WO2017076138A1 - 吡咯喹啉醌b晶型及其制备方法 - Google Patents

吡咯喹啉醌b晶型及其制备方法 Download PDF

Info

Publication number
WO2017076138A1
WO2017076138A1 PCT/CN2016/100658 CN2016100658W WO2017076138A1 WO 2017076138 A1 WO2017076138 A1 WO 2017076138A1 CN 2016100658 W CN2016100658 W CN 2016100658W WO 2017076138 A1 WO2017076138 A1 WO 2017076138A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
pyrroloquinoline quinone
pyrroloquinoline
quinone
crystal
Prior art date
Application number
PCT/CN2016/100658
Other languages
English (en)
French (fr)
Inventor
朱理平
梅雪锋
王建荣
Original Assignee
诸城市浩天药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 诸城市浩天药业有限公司 filed Critical 诸城市浩天药业有限公司
Priority to JP2018541469A priority Critical patent/JP2018533623A/ja
Priority to US15/772,946 priority patent/US10562895B2/en
Priority to EP16861406.3A priority patent/EP3372602B1/en
Publication of WO2017076138A1 publication Critical patent/WO2017076138A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the invention belongs to the technical field of chemical drugs and crystal form processes, in particular to a crystal form of pyrroloquinoline quinone B and a preparation method thereof.
  • polymorphism phenomenon refers to a phenomenon in which solid materials are arranged in two or more different spatial arrangements to form solid states having different physicochemical properties.
  • polymorphs include multi-component crystalline forms such as organic solvates, hydrates, and the like.
  • Drug polymorphism is widespread in drug development and is an inherent property of organic small molecule compounds. Theoretically, small molecule drugs can have an infinite number of crystal packing methods - polymorphs. Studies have shown that the number of drug polymorphs found is directly proportional to the time and resources of the research they are investigating. Like Lipitor, the world's highest-selling drug to date, there are as many as 35 patents for patent protection.
  • Polymorphism is not only controlled by the internal structure of the molecule itself, functional group properties, intramolecular and intermolecular interactions, but also by drug synthesis process design, crystallization and purification conditions, formulation excipient selection, formulation process Route and granulation methods, as well as storage conditions, packaging materials and other factors. Different crystal forms have different colors, melting points, dissolution, dissolution properties, chemical stability, reactivity, mechanical stability, etc. These physical and chemical properties or processability sometimes directly affect the safe and effective performance of the drug. Therefore, crystal research and control has become an important research content in the drug development process.
  • Crystallization studies include two stages of crystal discovery and crystal form optimization.
  • the crystal discovery stage a variety of crystallization methods are used, such as melt crystallization, solution evaporation, rapid cooling and suspension crystallization, by changing the crystallization conditions, solvent The external factors affecting the crystallization of the drug, such as temperature, speed and ratio of suspended solvent.
  • Using a high-throughput sample preparation platform hundreds of crystallization tests were prepared simultaneously, and new crystal forms were prepared and discovered using micro sample preparation techniques and analytical testing methods.
  • the new crystal form process amplification and preparation conditions are explored, and various solid characterization methods such as X-ray diffraction, solid state nuclear magnetic resonance, Raman spectroscopy, infrared spectroscopy, etc.
  • PQQ is a newly discovered B vitamin, a coenzyme of oxidoreductase different from pyridine nucleotide and riboflavin. Its unique structure of ortho-steroids gives it unique physicochemical properties and The physiological functions have broad application prospects in food, medicine, agriculture and other industries. PQQ has a polymorphic phenomenon, but there are no reports of polymorphic patents.
  • the invention reports a new crystal form of PQQ: B crystal form on the basis of adopting a new crystal nucleation mode and crystallization conditions.
  • One of the objects of the present invention is to provide a crystal form of pyrroloquinoline quinone B which has high crystallinity, low hygroscopicity and can form a regular crystal form.
  • a crystal form of pyrroloquinoline quinone B having three or more characteristic diffraction peaks selected from the group consisting of 11.10 ⁇ 0.2° and 17.32 ⁇ 0.2. °, 19.40 ⁇ 0.2 °, 20.16 ⁇ 0.2 °, 20.53 ⁇ 0.2 °, 22.57 ⁇ 0.2 °, 26.14 ⁇ 0.2 °, 29.95 ⁇ 0.2 °, 32.06 ⁇ 0.2 °.
  • the pyrroloquinoline quinone B crystal form has three or more characteristic diffraction peaks selected from the group consisting of 11.10, 15.69, 16.52, 17.32, 18.64, 19.40, 20.16, 20.53, 21.77, 22.57, 24.05, 24.36, 25.42, 26.14, 27.05, 27.60, 28.15, 29.37, 29.95, 32.06, 33.96, 35.62, 36.97, 38.09 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the pyrroloquinoline quinone B crystal form is substantially as shown in FIG.
  • the thermal weight loss analysis spectrum of the pyrroloquinoline quinoid B crystal form has a decomposition temperature of 260 °C.
  • the pyrroloquinoline quinone B crystal form is amorphous.
  • thermogravimetric analysis of the pyrroloquinoline quinoid B crystal form is substantially as shown in FIG.
  • the differential scanning calorimetry of the pyrroloquinoline quinoid B crystal form is substantially as shown in FIG.
  • the IR spectra of Form B at least 3344cm -1, 3257cm -1, 2808 cm -1, 2596cm -1, 1745cm -1, 1726cm -1, 1710cm -1, 1691cm -1, 1643 cm -1 , 1508 cm -1 , 1402 cm -1 , 1336 cm -1 , 1261 cm -1 , 1207 cm -1 , 1080 cm -1 , and 769 cm -1 have characteristic peaks.
  • the infrared spectrum of the pyrroloquinoline quinone B crystal form is substantially as shown in FIG.
  • the hygroscopicity analysis of the B crystal form adsorbs one molecule of water at a relative humidity of 85-95% to form a monohydrate.
  • a method for preparing a crystal form of pyrroloquinoline quinone B which is simple in operation and reproducible.
  • the preparation method comprises the steps of: placing pyrroloquinoline citric acid (PQQ acid) in a vacuum drying oven at room temperature, and heating, that is,
  • pyrroloquinoline decanoic acid means 4,5-dioxo-4,5-dihydro-1hydro-pyrrole[2,3-f]quinoline-2,7,9-tricarboxylic acid.
  • the temperature is raised to 130-160 ° C, preferably 140-150 ° C.
  • the holding time is 3-5 hours.
  • the crystal form of pyrroloquinoline quinone B provided by the invention has high crystallinity, small hygroscopicity, and can form a regular crystal form, which is beneficial to the process and physical property of the drug, and improves the drug-forming property; the preparation method The process is simple, easy to operate and reproducible.
  • Example 1 is an X-ray powder diffraction (XRPD) pattern of the PQQ B crystal form provided in Example 1;
  • Example 2 is a thermogravimetric analysis (TG) diagram of the PQQ B crystal form provided in Example 1;
  • DSC differential scanning calorimetry
  • Example 4 is an infrared spectrum (IR) diagram of the PQQ B crystal form provided in Example 1;
  • Figure 5 is a graph showing the hygroscopicity analysis (DVS) of the PQQ B crystal form provided in Example 1.
  • the pyrroloquinoline quinone B crystal form provided by the invention is subjected to X-ray powder diffraction (XRPD), thermogravimetric analysis (TG), differential scanning calorimetry (DSC), infrared (IR) and hygroscopicity analysis (DVS). Characterization by solid state methods.
  • XRPD X-ray powder diffraction
  • TG thermogravimetric analysis
  • DSC differential scanning calorimetry
  • IR infrared
  • DVD hygroscopicity analysis
  • the X-ray powder diffraction analysis of the pyrroquinoline quinone B crystalline solid sample prepared in Example 1 was carried out by using Bruker D8BdvBnce type diffractometer of Bruker Instruments Co., Ltd., using Cu-K ray.
  • the voltage is 40 kV
  • the current is 40 mA
  • the step size is 0.02 degrees
  • each step takes 0.1 second.
  • the analysis results are shown in Figure 1.
  • the solid sample of pyrroloquinoline quinone B prepared in Example 1 was subjected to thermogravimetric analysis using a thermogravimetric analyzer of the German TG20F3 type, and the atmosphere was nitrogen gas at a heating rate of 10 deg/min.
  • the analysis results are shown in Figure 2.
  • the pyrroquinoline quinone B crystalline solid sample prepared in Example 1 was subjected to differential scanning calorimetry, which was detected by a DSC 8500 differential calorimeter from Elmer, USA, and the atmosphere was nitrogen, and the heating rate was 10 Celsius / minute.
  • the analysis results are shown in Figure 3.
  • the solid sample of pyrroloquinoline quinone B prepared in Example 1 was analyzed by infrared spectroscopy, and it was detected at room temperature by Nicolet-MBgnB FT-IR 750 infrared spectroscopy analyzer of Nikola, USA. The detection range was: 4000- 350cm -1 wave number. The analysis results are shown in Figure 4.
  • the pyrroloquinoline quinone B crystalline solid sample prepared in Example 1 was subjected to hygroscopicity analysis.
  • the analysis results are shown in Figure 5. It can be seen from Fig. 5 that at a relative humidity of 85-95%, the crystal form adsorbs one molecule of water and is converted into a monohydrate compound, and its water absorption rate is low and the growth is slow, indicating that the crystal form has low hygroscopicity.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

本发明属于化学药物及晶型工艺技术领域，尤其涉及吡咯喹啉醌B晶型及其制备方法，本发明运用X-射线粉末衍射分析、热失重分析、差示扫描量热分析等手段对吡咯喹啉醌B晶型进行了全面表征，发现吡咯喹啉醌B晶型结晶度高、吸湿性小，并可形成规整的晶体型态，有利于药物的工艺处理和物化性能的改善，提高成药性能。本发明提供的吡咯喹啉醌B晶型的制备方法简单，容易控制，重现性好。

Description

吡咯喹啉醌B晶型及其制备方法 技术领域
本发明属于化学药物及晶型工艺技术领域，尤其涉及吡咯喹啉醌B晶型及其制备方法。
背景技术
多晶型现象是指固体物质以两种或两种以上的不同空间排列方式，形成的具有不同物理化学性质的固体状态的现象。在药物研究领域，多晶型包括了有机溶剂化物、水合物等多组分晶体形式。
药物多晶现象在药物开发过程中广泛存在，是有机小分子化合物固有的特性。理论上小分子药物可以有无限多的晶体堆积方式-多晶型，研究表明，药物多晶型的发现数量与其投入的研究的时间和资源成正比例。如世界上迄今为止销售额最高的药物-Lipitor，申请专利保护的晶型就多达35种。
多晶型现象不光受到分子本身的空间结构和官能基团性能，分子内和分子间的相互作用等内在因素的控制，它还受药物合成工艺设计、结晶和纯化条件、制剂辅料选择、制剂工艺路线和制粒方法、以及储存条件、包装材料等诸方面因素的影响。不同晶型具有不同的颜色、熔点、溶解、溶出性能、化学稳定性、反应性、机械稳定性等，这些物理化学性能或可加工性能有时直接影响到药物的安全、有效性能。因此晶型研究和控制成为药物研发过程中的重要研究内容。
晶型研究包括晶体发现和晶型优选的两个阶段，在晶体发现阶段，主要采用多种结晶手段，如熔融结晶，溶液挥发，快速冷却和混悬法的结晶方法，通过改变结晶条件，溶剂，温度，速度和混悬溶剂比例等影响药物结晶的外部因素。采用高通量样品制备平台，同时制备数百次结晶试验，运用微量样品制备技术和分析测试手段制备和发现新的晶型。在晶型优选阶段，要对新的晶型工艺放大和制备条件摸索，采用多种固体表征手段，如X-射线衍射，固体核磁共振，拉曼光谱，红外光谱等手段对晶型表征，另外，要采用DSC、TGB、DVS、HPLC等对晶型进行物化性能研究，比较不同晶型的吸湿性、化学稳定性、物理状态稳定性、可加工性等进行研究。最后选择最为优选的固体形态进行开发。
吡咯喹啉醌(PQQ，Pyrroloquinoline quinone)的化学名为：
4,5-Dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricBrboxylic Bcid，其化学结构式如下：
Figure PCTCN2016100658-appb-000001
PQQ是一种新发现的B族维生素，是一种不同于吡啶核苷酸和核黄素的氧化还原酶的辅酶，其邻位醌类化合物的独特结构，使其具有独特的理化性质和多种生理功能，在食品、医药、农业等行业有广泛的应用前景。PQQ具有多晶型现象，但目前暂无多晶型专利的报道。
本发明在综合采用新的结晶成核方式和结晶条件的基础上，报道一种PQQ的新晶型：B晶型。
发明内容
本发明的目的之一在于：提供一种结晶度高、吸湿性小、并能形成规整晶体形态的吡咯喹啉醌B晶型。
本发明第一方面，提供一种吡咯喹啉醌B晶型，所述吡咯喹啉醌B晶型具有3个或3个以上选自下组的特征衍射峰：11.10±0.2°、17.32±0.2°、19.40±0.2°、20.16±0.2°、20.53±0.2°、22.57±0.2°、26.14±0.2°、29.95±0.2°、32.06±0.2°。
在另一优选例中，所述吡咯喹啉醌B晶型具有3个或3个以上选自下组的特征衍射峰：11.10、15.69、16.52、17.32、18.64、19.40、20.16、20.53、21.77、22.57、24.05、24.36、25.42、26.14、27.05、27.60、28.15、29.37、29.95、32.06、33.96、35.62、36.97、38.09±0.2°。
在另一优选例中，所述吡咯喹啉醌B晶型的X-射线粉末衍射图基本如图1所示。
在另一优选例中，所述吡咯喹啉醌B晶型的热失重分析图谱的分解温度为260℃。
在另一优选例中，所述吡咯喹啉醌B晶型为无水晶型。
在另一优选例中，所述吡咯喹啉醌B晶型的热失重分析图基本如图2所示。
在另一优选例中，所述吡咯喹啉醌B晶型的差示扫描量热分析基本如图3所示。
在另一优选例中，所述B晶型的红外图谱至少在3344cm-1、3257cm-1、2808 cm-1、2596cm-1、1745cm-1、1726cm-1、1710cm-1、1691cm-1、1643cm-1、1508cm-1、1402cm-1、1336cm-1、1261cm-1、1207cm-1、1080cm-1、769cm-1处具有特征峰。
在另一优选例中，所述吡咯喹啉醌B晶型的红外光谱基本如图4所示。
在另一优选例中，所述B晶型的吸湿性分析在相对湿度85-95％吸附一分子水，形成一水化合物。
本发明第二方面，提供一种操作简单，重现性好的吡咯喹啉醌B晶型的制备方法。
所述制备方法包括以下步骤：室温下将吡咯喹啉醌酸(PQQ酸)置于真空干燥箱内，升温，即得，
其中，吡咯喹啉醌酸是指4,5-二氧-4,5-二氢化-1氢-吡咯[2,3-f]喹啉-2,7,9-三羧酸。
在另一优选例中，升温至130-160℃，较佳地为140-150℃。
在另一优选例中，升温之后，保持时间为3-5小时。
由于采用了上述技术方案，本发明的有益效果是：
本发明提供的吡咯喹啉醌B晶型，其结晶度高、吸湿性小，并可形成规整的晶体型态，有利于药物的工艺处理和物化性能的改善，提高成药性能；所述制备方法工艺简单，易于操作，重现性好。
附图说明
图1是实施例1提供的PQQ B晶型的X-射线粉末衍射(XRPD)图；
图2是实施例1提供的PQQ B晶型的热失重分析(TG)图；
图3是实施例1提供的PQQ B晶型的差示扫描量热分析(DSC)图；
图4是实施例1提供的PQQ B晶型的红外光谱(IR)图；
图5是实施例1提供的PQQ B晶型的吸湿性分析(DVS)图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合附图及实施例，对本发明进行进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定本发明。
实施例1
将20.0mg PQQ酸置于玻璃瓶中，玻璃瓶敞口放置于真空干燥箱，升温至140℃，保持5h，即得到吡咯喹啉醌B晶型20.00mg，产率为100％，吡咯喹啉醌B晶型为红色结晶性粉末。
实施例2
将20.0mg PQQ酸置于玻璃瓶中，玻璃瓶敞口放置于真空干燥箱，升温至140℃，保持6h，即得到吡咯喹啉醌B晶型20.00mg，产率为100％，吡咯喹啉醌B晶型为红色结晶性粉末。
实施例3
将20.0mg PQQ酸置于玻璃瓶中，玻璃瓶敞口放置于真空干燥箱，升温至140℃，保持5.5h，即得到吡咯喹啉醌B晶型20.00mg，产率为100％，吡咯喹啉醌B晶型为红色结晶性粉末。
实施例4
将20.0mg PQQ酸置于玻璃瓶中，玻璃瓶敞口放置于真空干燥箱，升温至150℃，保持4.5h，即得到吡咯喹啉醌B晶型20.00mg，产率为100％，吡咯喹啉醌B晶型为红色结晶性粉末。
实施例5
将20.0mg PQQ酸置于玻璃瓶中，玻璃瓶敞口放置于真空干燥箱，升温至150℃，保持5h，即得到吡咯喹啉醌B晶型20.00mg，产率为100％，吡咯喹啉醌B晶型为红色结晶性粉末。
实施例6
将20.0mg PQQ酸置于玻璃瓶中，玻璃瓶敞口放置于真空干燥箱，升温至150℃，保持6h，即得到吡咯喹啉醌B晶型20.00mg，产率为100％，吡咯喹啉醌B晶型为红色结晶性粉末。
本发明提供的吡咯喹啉醌B晶型，通过X-射线粉末衍射(XRPD)、热失重分析(TG)、差示扫描量热分析(DSC)、红外(IR)以及吸湿性分析(DVS)等固态方法表征。
对实施例1制得的吡咯喹啉醌B晶型固体样品进行X-射线粉末衍射分析，其采用德国布鲁克仪器有限公司Bruker D8BdvBnce型的衍射仪，采用Cu-K射线
Figure PCTCN2016100658-appb-000002
电压为40千伏，电流为40毫安，步径：0.02度，每步用时0.1秒。其分析结果见图1。
对实施例1制得的吡咯喹啉醌B晶型固体样品进行热失重分析，其采用德国耐驰科学仪器有限公司TG20F3型热重分析仪，气氛为氮气，升温速率为10度/分钟。其分析结果见图2。
对实施例1制得的吡咯喹啉醌B晶型固体样品进行差示扫描量热分析，其采用美国铂金埃尔默公司的DSC 8500差示量热仪检测，气氛为氮气，加热速度为10摄氏度/分钟。其分析结果见图3。
对实施例1制得的吡咯喹啉醌B晶型固体样品进行红外光谱分析，其采用美国尼高力公司的Nicolet-MBgnB FT-IR 750红外光谱分析仪于室温检测，检测范围为：4000-350cm-1波数。其分析结果见图4。
对实施例1制得的吡咯喹啉醌B晶型固体样品进行吸湿性分析。其分析结果见图5。从图5中可以看出，在相对湿度85-95％，该晶型吸附一分子水，转变为一水化合物，其吸水率较低且增加缓慢，说明该晶型的吸湿性小。
以上所述仅为本发明的较佳实施例而已，并不用以限制本发明，凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明的保护范围之内。

Claims (13)

  1. 一种吡咯喹啉醌B晶型，其特征在于，所述吡咯喹啉醌B晶型具有3个或3个以上选自下组的特征衍射峰：11.10±0.2°、17.32±0.2°、19.40±0.2°、20.16±0.2°、20.53±0.2°、22.57±0.2°、26.14±0.2°、29.95±0.2°、32.06±0.2°。
  2. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述吡咯喹啉醌B晶型具有3个或3个以上选自下组的特征衍射峰：11.10、15.69、16.52、17.32、18.64、19.40、20.16、20.53、21.77、22.57、24.05、24.36、25.42、26.14、27.05、27.60、28.15、29.37、29.95、32.06、33.96、35.62、36.97、38.09±0.2°。
  3. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述吡咯喹啉醌B晶型的X-射线粉末衍射图基本如图1所示。
  4. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述B晶型的热失重分析图谱的分解温度为260℃。
  5. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述B晶型为无水晶型。
  6. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述吡咯喹啉醌B晶型的热失重分析图基本如图2所示。
  7. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述吡咯喹啉醌B晶型的差示扫描量热分析基本如图3所示。
  8. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述B晶型的红外图谱至少在3344cm-1、3257cm-1、2808cm-1、2596cm-1、1745cm-1、1726cm-1、1710cm-1、1691cm-1、1643cm-1、1508cm-1、1402cm-1、1336cm-1、1261cm-1、1207cm-1、1080cm-1、769cm-1处具有特征峰。
  9. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述吡咯喹啉醌B晶型的红外光谱基本如图4所示。
  10. 如权利要求1所述的吡咯喹啉醌B晶型，其特征在于，所述B晶型的吸湿性分析在相对湿度85-95％吸附一分子水，形成一水化合物。
  11. 一种制备如权利要求1所述的吡咯喹啉醌B晶型的方法，包括步骤：室温下将吡咯喹啉醌酸置于真空干燥箱内，升温，即得。
  12. 如权利要求11所述的方法，其特征在于，升温至130-160℃。
  13. 如权利要求11所述的方法，其特征在于，升温之后，保持时间为3-5 小时。
PCT/CN2016/100658 2015-11-02 2016-09-28 吡咯喹啉醌b晶型及其制备方法 WO2017076138A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2018541469A JP2018533623A (ja) 2015-11-02 2016-09-28 ピロロキノリンキノンのｂ結晶形およびその製造方法
US15/772,946 US10562895B2 (en) 2015-11-02 2016-09-28 Pyrroloquinoline quinone B crystal form and preparation method therefor
EP16861406.3A EP3372602B1 (en) 2015-11-02 2016-09-28 Pyrroloquinoline quinone b crystal form and preparation method therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510734349.2 2015-11-02
CN201510734349.2A CN105218543B (zh) 2015-11-02 2015-11-02 吡咯喹啉醌b晶型及其制备方法

Publications (1)

Publication Number Publication Date
WO2017076138A1 true WO2017076138A1 (zh) 2017-05-11

Family

ID=54987876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/100658 WO2017076138A1 (zh) 2015-11-02 2016-09-28 吡咯喹啉醌b晶型及其制备方法

Country Status (5)

Country Link
US (1) US10562895B2 (zh)
EP (1) EP3372602B1 (zh)
JP (1) JP2018533623A (zh)
CN (1) CN105218543B (zh)
WO (1) WO2017076138A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125899A (zh) * 2019-06-24 2020-12-25 浙江医药股份有限公司 吡咯并喹啉醌二钠盐结晶、其制备方法及包含其的组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218543B (zh) * 2015-11-02 2017-05-10 诸城市浩天药业有限公司 吡咯喹啉醌b晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011007633A1 (ja) * 2009-07-16 2011-01-20 三菱瓦斯化学株式会社 ピロロキノリンキノンのナトリウム塩結晶
WO2015159236A1 (en) * 2014-04-16 2015-10-22 Anthem Biosciences Private Limited Polymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use
CN105218543A (zh) * 2015-11-02 2016-01-06 诸城市浩天药业有限公司 吡咯喹啉醌b晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011055796A1 (ja) 2009-11-06 2013-03-28 三菱瓦斯化学株式会社 ピロロキノリンキノンのフリー体
JP5979376B2 (ja) * 2010-11-26 2016-08-24 三菱瓦斯化学株式会社 溶解性の高いピロロキノリンキノン塩及びその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011007633A1 (ja) * 2009-07-16 2011-01-20 三菱瓦斯化学株式会社 ピロロキノリンキノンのナトリウム塩結晶
WO2015159236A1 (en) * 2014-04-16 2015-10-22 Anthem Biosciences Private Limited Polymorphic forms of 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid and its disodium salt, process for their preparation and their use
CN105218543A (zh) * 2015-11-02 2016-01-06 诸城市浩天药业有限公司 吡咯喹啉醌b晶型及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112125899A (zh) * 2019-06-24 2020-12-25 浙江医药股份有限公司 吡咯并喹啉醌二钠盐结晶、其制备方法及包含其的组合物

Also Published As

Publication number Publication date
EP3372602A1 (en) 2018-09-12
EP3372602A4 (en) 2019-04-10
JP2018533623A (ja) 2018-11-15
US20180319792A1 (en) 2018-11-08
US10562895B2 (en) 2020-02-18
CN105218543A (zh) 2016-01-06
EP3372602B1 (en) 2021-07-14
CN105218543B (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
CN108864077B (zh) 小檗碱有机酸盐的固体形式及其制备方法
AU2015296117B2 (en) Crystalline free bases of C-Met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof
WO2017076138A1 (zh) 吡咯喹啉醌b晶型及其制备方法
CN105315278B (zh) 吡咯喹啉醌a晶型及其制备方法
AU2021303629A1 (en) Crystal form of upadacitinib, preparation method therefor, and use thereof
CN109776416B (zh) 一种草乌甲素c晶型及其制备方法与应用
CN106854203B (zh) 枸橼酸舒芬太尼的新晶型及其制备方法
JP2022525120A (ja) ブレイアコニチンａのｄ結晶形及びその製造方法と使用
WO2015113370A1 (zh) 一种甜菊糖a苷晶体及其制备方法和用途
WO2018196681A1 (zh) 硝苯地平与异烟酰胺的共晶
WO2015113369A1 (zh) 一种甜菊糖a苷晶体及其制备方法和用途
TW201336861A (zh) 雄甾－３β，５α，６β－三醇的晶型化合物及其製備方法
EP3473623B1 (en) Crystal forms of nbi-98854, preparation method therefor and use thereof
CN113549011A (zh) 德度司他的共晶或盐及其制备方法和用途
US10815232B2 (en) Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof
CN111732586A (zh) 含炔基化合物盐的晶型、制备方法及应用
CN107698563B (zh) 制备马来酸来那替尼晶型的方法
CN115872918A (zh) 一种吲哚布芬晶型e及其制备方法
CN110964017A (zh) 瑞博西尼单琥珀酸盐的多晶型物及其制备方法和用途
JP2021535218A (ja) Ｄｐｐ−ｉｖ阻害剤の血糖降下薬の新しい結晶形およびその調製方法
CN107739358B (zh) 一种大豆苷元无水晶型ii、制备方法及其医药用途
WO2017016512A1 (zh) 马赛替尼甲磺酸盐的新晶型及其制备方法
CN106518952B (zh) 醋酸曲安奈德晶型b、其制备方法、包含所述晶型b的药物组合物和用途
CN109666034B (zh) 乳酸左氧氟沙星晶型及其制备方法和应用
CN115745913B (zh) 曲法罗汀多晶型及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16861406

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15772946

Country of ref document: US

Ref document number: 2018541469

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016861406

Country of ref document: EP